Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes-Reference-Cited by-同舟云学术

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

Published:2021-06-29 Issue:3 Volume:12 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Tada Takuya¹,Dcosta Belinda M.¹,Samanovic Marie I.²³,Herati Ramin S.²³,Cornelius Amber²³,Zhou Hao¹,Vaill Ada⁴,Kazmierski Wes⁴,Mulligan Mark J.²³,Landau Nathaniel R.¹^ORCID

Affiliation:

1. Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA

2. NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York, USA

3. Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA

4. Biohaven Pharmaceuticals, Inc., New Haven, Connecticut, USA

Abstract

The rapid evolution of SARS-CoV-2 variants has raised concerns with regard to their potential to escape from vaccine-elicited antibodies and anti-spike protein monoclonal antibodies. We report here on an analysis of sera from recovered patients and vaccinated individuals and on neutralization by Regeneron therapeutic monoclonal antibodies.

Funder

HHS | NIH | OSC | Common Fund

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mBio.00696-21

Reference51 articles.

1. Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide

2. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity

3. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types